The omics pipeline: the pathway to drug discovery and personalised/precision medicine

The last 20 years has seen rapid advances in genomics, proteomics and other omics technologies, with both the human genome proteome now being at >90% completion high stringency.1 This same period also a paradigm shift medical treatment from traditional ‘one size fits all’ approach, where all patients receive standardised for particular disease, to personalised/precision medicine (PM) approach is tailored an individual based on understanding of their systems biology (comprehensive in-depth monitoring genes, proteins) disease related pathways, lifestyle environmental factors.2 success PM closely linked discovery validation sensitive specific protein peptide disease-related biomarkers, subsequent development rapid, robust, clinical assays detection surveillance. pipeline (genomics, transcriptomics, proteomics, metabolomics, interactomics microbiomics) can provide overall perspective health leading identification potential biomarkers surveillance novel drug targets.3 In this presentation I will address key components toolbox illustrate how they have advanced our knowledge underlying giving improved foundation advancement cancer. References 1. Adhikari S, et al. A high-stringency blueprint proteome. Nat Commun 2020; 11: 5301. 2. Su M, Proteomics, personalized Cancers (Basel). 2021; 13: 2512. 3. Chen R, Personal profiling reveals dynamic molecular phenotypes. Cell 2012; 148: 1293–307.